Patent application number | Description | Published |
20120093840 | TARGETED DELIVERY OF FACTOR VIII PROTEINS TO PLATELETS - The invention described herein relates to novel molecules and polypeptides comprising at least one amino acid sequence having significant identity with (homology to) human Factor VIII or biologically active portion(s) thereof, related molecules (such as nucleic acids encoding such polypeptides), compositions (such as pharmaceutical formulations) comprising such polypeptides, and methods of making and using such polypeptides. | 04-19-2012 |
20120172303 | Growth Hormones with Prolonged In-Vivo Efficacy - The present invention relates to polypeptide compound optimized for subcutaneous administration, exemplified by growth hormone conjugates having a linker providing non-covalent binding to albumin. | 07-05-2012 |
20120309944 | Growth Hormones With Prolonged In-Vivo Efficacy - The invention relates to growth hormone compounds with a protracted profile. The effect is obtained by linking an albumin binding residue via a hydrophilic spacer to growth hormone variants. Further described are methods of preparing and using such compounds. These growth hormone compounds are based on there altered profile considered particular useful in therapy. | 12-06-2012 |
20120322738 | CONJUGATED FVIII VARIANTS - The present invention relates to conjugated Factor VIII variants. The present invention in particular relates to conjugated FVIII variants comprising different polymeric groups as well as use thereof. | 12-20-2012 |
20130004524 | Conjugated Proteins - The present invention relates to modified therapeutic proteins, such as e.g. coagula-tion factors. In particular, the present invention relates to conjugated Factor VIII molecules such as e.g. FVII, FVIII, or FIX comprising a hydrophobic side group. | 01-03-2013 |
20130012684 | Purification Method - The present invention provides a method for purification of a protein that is conjugated to an albumin binding moiety from a mixture comprising (i) said protein in said conjugated form and (ii) said protein in a form that is not conjugated to said albumin-binding moiety, the method comprising: (a) providing a solid support comprising a substance capable of specifically binding to the albumin binding moiety; (b) contacting said solid support of (a) with said mixture comprising protein and conjugated protein under suitable conditions for binding of the albumin binding moiety to the substance as defined in (a); and (c) eluting components bound to the solid support. | 01-10-2013 |
20130040888 | Factor VIII Molecules With Reduced VWF Binding - The present invention relates to a recombinant Factor VIII molecule, wherein said molecule has reduced vWF binding capacity, and wherein said molecule is covalently conjugated with at least one side group. | 02-14-2013 |
20130330360 | ANTAGONISTIC DR3 LIGANDS - The present disclosure relates to treatment of inflammatory diseases. In particular, the present disclosure relates to antagonistic DR | 12-12-2013 |
20130336984 | ANTAGONISTIC DR3 LIGANDS - The present invention relates to treatment of inflammatory diseases. In particular, the present invention relates to antagonistic DR3 ligands useful for treating inflammatory diseases. | 12-19-2013 |
20140107324 | Growth Hormones with Prolonged In-Vivo Efficacy - The invention relates to growth hormone compounds with a protracted profile. The effect is obtained by linking an albumin binding residue via a hydrophilic spacer to growth hormone variants. Further described are methods of preparing and using such compounds. These growth hormone compounds are based on there althered profile considered particular useful in therapy. | 04-17-2014 |
20140294853 | ANTAGONISTIC DR3 LIGANDS - The present invention relates to treatment of inflammatory diseases. In particular, the present invention relates to antagonistic DR3 ligands useful for treating inflammatory diseases. | 10-02-2014 |
20140329750 | Growth Hormones with Prolonged In-Vivo Efficacy - The present invention relates to polypeptide compound optimized for subcutaneous administration, exemplified by growth hormone conjugates having a linker providing non-covalent binding to albumin. | 11-06-2014 |